Clarivate Science Holdings Corporation announced on November 12, 2026 the expiration and final results of its cash tender offers for two series of outstanding senior notes, with a total of $533,000,000 aggregate principal amount accepted for purchase following a 2% upsize exercise.

Key Highlights

  • Total accepted: $533,000,000 aggregate principal amount of notes accepted for purchase across both series.
  • 2028 Notes: $611,502,000 tendered; $415,000,000 accepted at a proration factor of approximately 67.9%, at a total consideration of $979.08 per $1,000 principal amount.
  • 2029 Notes: $259,297,000 tendered; $118,000,000 accepted at a proration factor of approximately 45.5%, at a total consideration of $928.75 per $1,000 principal amount.
  • Upsize exercised: The company exercised its right to increase the aggregate principal amount sought by 2% for each series, raising the 2028 Notes Series Cap to $415,000,000 and the 2029 Notes Series Cap to $118,000,000.
  • Expiration and settlement: The offers expired at 5:00 p.m. New York City time on November 10, 2026, with settlement scheduled for November 13, 2026.
  • Accrued coupon payment: Holders whose notes are accepted for purchase will also receive an accrued coupon payment on the settlement date.

Clarivate Science Holdings Closes Dual-Series Tender Offers With Full Upsize

According to the filing, Clarivate Science Holdings Corporation, a wholly-owned subsidiary of Clarivate Plc (NYSE:CLVT), conducted cash tender offers for its outstanding 3.875% Senior Secured Notes due 2028 and 4.875% Senior Notes due 2029. The offers were launched under an Offer to Purchase dated November 4, 2026, and expired at 5:00 p.m. New York City time on November 10, 2026. The company disclosed that all conditions to the offers were satisfied or waived on or prior to the expiration date.

The filing disclosed that the company exercised its right to increase the aggregate principal amount accepted by 2% of the outstanding aggregate principal amount of each series. As a result, the 2028 Notes Series Cap was set at $415,000,000 (up from an initial $400,000,000) and the 2029 Notes Series Cap at $118,000,000 (up from an initial $100,000,000). For the 2028 Notes, $611,502,000 aggregate principal amount was validly tendered against an outstanding balance of $750,000,000 prior to the tender offer, with $415,000,000 accepted at a proration factor of approximately 67.9%. For the 2029 Notes, $259,297,000 was tendered against an outstanding balance of $900,000,000, with $118,000,000 accepted at a proration factor of approximately 45.5%.

The 2028 Notes total consideration of $979.08 per $1,000 principal amount was determined at 2:00 p.m. New York City time on November 10, 2026, in the manner described in the tender offer documents, according to the filing. The 2029 Notes total consideration was set at $928.75 per $1,000 principal amount. The settlement date is November 13, 2026, at which point accepted holders will also receive an accrued coupon payment. Notes tendered but not accepted will be returned promptly to tendering holders. Citigroup Global Markets Inc. served as dealer manager and Global Bondholder Services Corporation served as tender and information agent for the offers.

What Was Disclosed

Clarivate Science Holdings Corporation reported the final results of its tender offers for two series of senior notes, disclosing proration factors, total consideration prices, aggregate amounts tendered and accepted, a 2% upsize exercise, and a settlement date of November 13, 2026.